Full Breakdown
TroFuse-005 Shows Survival Benefit for Advanced Endometrial Cancer
5/19/2026, 9:50:50 PM
Trial Overview and Primary Results
The global, open-label Phase 3 TroFuse-005 trial (NCT06132958) compared sacituzumab tirumotecan (sac-TMT) with physician’s choice chemotherapy (doxorubicin or paclitaxel) in 776 patients with advanced or recurrent endometrial carcinoma or carcinosarcoma who had previously received platinum-based chemotherapy and anti-PD-1/PD-L1 immunotherapy. At a pre-specified interim analysis, sac-TMT achieved statistically significant improvements in overall survival (OS) and progression-free survival (PFS) versus chemotherapy, meeting both primary endpoints. The trial also met its key secondary endpoint of objective response rate, and the safety profile remained consistent with earlier studies, with no new safety signals reported.
Background: Endometrial Cancer Burden and TROP2 Targeting
Endometrial cancer is the most common uterine malignancy, accounting for over 90 % of uterine body cancers. In the United States, an estimated 68,270 new cases and 14,450 deaths are expected in 2026, making it one of the few cancers with rising incidence and mortality worldwide. The transmembrane protein TROP2 is overexpressed on many solid-tumor cells, including endometrial tumors, providing a rationale for antibody-drug conjugates (ADCs) that deliver cytotoxic payloads directly to cancer cells.
Study Design, Patient Population, and Dosing
Patients were randomized 1:1 to receive either sac-TMT 4 mg/kg on Day 1 of a 14-day cycle, or chemotherapy (doxorubicin 60 mg/m² on Day 1 of a 21-day cycle, or paclitaxel 80 mg/m² on Days 1, 8, 15 of a 28-day cycle). Eligibility required prior exposure to platinum chemotherapy and anti-PD-1/PD-L1 agents, either sequentially or concurrently. The trial’s primary endpoints were OS and PFS; secondary endpoints included duration of response, adverse-event incidence, treatment discontinuation, and quality-of-life measures.
Sacituzumab Tirumotecan: Mechanism and Development
Sac-TMT is a TROP2-directed ADC that couples a belotecan-derived topoisomerase I inhibitor payload to a proprietary bifunctional linker designed to maximize tumor delivery while limiting systemic exposure. The ADC was co-developed with Kelun-Biotech, which holds exclusive rights for development, manufacturing, and commercialization outside Greater China. Kelun-Biotech granted Merck these rights under a $1.4 billion agreement in 2022, later expanded to a $9.3 billion commitment for seven additional ADC candidates.
TroFuse Program Scope
The TroFuse clinical development program now comprises 17 ongoing global Phase 3 trials across more than nine disease areas, enrolling over 15,000 patients. Ten of these trials focus on women’s cancers, evaluating sac-TMT as monotherapy or in combination with immunotherapies for endometrial, bladder, breast, cervical, gastric, non-small cell lung, and ovarian cancers.
Official Statements & Responses
Merck highlighted that the trial’s results address a critical unmet need for patients whose disease progresses after platinum and immunotherapy. The company noted that the data will be presented at an upcoming medical meeting and discussed with regulators worldwide. Merck also emphasized the strategic importance of the TroFuse program in advancing its ADC pipeline and improving outcomes for women’s cancers.
Criticism & Opposition
Analysts caution that the magnitude of the OS and PFS benefit was not disclosed, limiting immediate assessment of clinical impact. GlobalData’s Biswajit Podder stressed that additional data, particularly for sac-TMT combined with pembrolizumab (Keytruda), are needed before the regimen can be considered a worldwide standard. The absence of a defined regulatory filing timeline was also noted.
Conflicting Reports & Gaps
Sources agree on the trial’s positive primary outcomes but differ on the level of detail provided. While Reuters reported the drug’s inclusion in the FDA’s Priority Voucher program, Merck’s own release did not quantify the expected review timeline. No quantitative efficacy or safety data were released, creating a gap for clinicians and payers.
What’s Next
Merck plans to present detailed results at a forthcoming oncology congress, likely the European Society for Medical Oncology meeting in October. The company expects to file a regulatory submission later in 2026, potentially leveraging the FDA’s priority review pathway.
Verbatim Quotes
- “These results show sac-TMT may be able to address a critical unmet need for certain patients with advanced endometrial cancer, one of the only cancers increasing in both incidence and mortality worldwide,” — Dr. Domenica Lorusso, Global Lead Investigator, Humanitas University
- “Despite recent advances, patients whose disease progresses following treatment with platinum and immunotherapy are urgently in need of new options, and these findings show for the first time that a TROP2 ADC may be an effective option in this setting.” — Dr. Domenica Lorusso
- “The scale and ambition of our expansive TroFuse program reflects our deep commitment to advancing one of the industry’s leading ADC pipelines to make a difference for more people facing cancer and builds on our legacy of leadership in gynecologic cancer research,” — Dr. Dean Y. Li, President, Merck Research Laboratories
- “These findings reinforce our belief that sac-TMT, with its proprietary bifunctional linker designed with the intent to maximize payload delivery to tumors while minimizing impact on healthy cells in the body, has the potential to become a cornerstone in the treatment of certain patients with advanced endometrial cancer.” — Dr. Dean Y. Li
- “There has been growing investor interest in sac-TMT’s potential over the past several months, and we expect today’s positive news to only increase that enthusiasm further,” — Vamil Divan, Analyst, Guggenheim Securities
- “For sac-TMT plus Keytruda to become a true worldwide standard, we will need to see data from the MSD-led global Phase III programmes that test this combination in populations more representative of wide practice and ideally against chemo immunotherapy comparators.” — Biswajit Podder, Analyst, GlobalData
